Rhythm Pharmaceuticals, Inc. (RYTM) stock
RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30268% above fair value
$116.61+9.13 (+8.49%)
Close on Nov 17, 2026Market cap $8.03BP/E –Yield –
Rhythm Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Rhythm Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$200.63M. For fiscal 2025 it was -$192.02M. The highest annual figure on record is -$10.57M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$192.02M | – |
| FY2024 | Dec 31, 2024 | -$265.50M | – |
| FY2023 | Dec 31, 2023 | -$184.36M | – |
| FY2022 | Dec 31, 2022 | -$179.16M | – |
| FY2021 | Dec 31, 2021 | -$170.06M | – |
| FY2020 | Dec 31, 2020 | -$136.58M | – |
| FY2019 | Dec 31, 2019 | -$146.00M | – |
| FY2018 | Dec 31, 2018 | -$78.42M | – |
| FY2017 | Dec 31, 2017 | -$32.41M | – |
| FY2016 | Dec 31, 2016 | -$25.91M | – |
| FY2015 | Dec 31, 2015 | -$10.57M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$48.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$52.36M | – |
| Q4 FY2025 | Dec 31, 2025 | -$47.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$52.65M | – |
| Q2 FY2025 | Jun 30, 2025 | -$45.30M | – |
| Q1 FY2025 | Mar 31, 2025 | -$47.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$41.26M | – |
| Q3 FY2024 | Sep 30, 2024 | -$43.89M | – |
| Q2 FY2024 | Jun 30, 2024 | -$40.48M | – |
| Q1 FY2024 | Mar 31, 2024 | -$139.89M | – |
| Q4 FY2023 | Dec 31, 2023 | -$41.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -$43.95M | – |
| Q2 FY2023 | Jun 30, 2023 | -$46.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$52.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$42.10M | – |
| Q3 FY2022 | Sep 30, 2022 | -$39.27M | – |
| Q2 FY2022 | Jun 30, 2022 | -$45.10M | – |
| Q1 FY2022 | Mar 31, 2022 | -$52.69M | – |
| Q4 FY2021 | Dec 31, 2021 | -$50.99M | – |
| Q3 FY2021 | Sep 30, 2021 | -$44.24M | – |
| Q2 FY2021 | Jun 30, 2021 | -$40.43M | – |
| Q1 FY2021 | Mar 31, 2021 | -$34.40M | – |
| Q4 FY2020 | Dec 31, 2020 | -$35.07M | – |
| Q3 FY2020 | Sep 30, 2020 | -$34.28M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.92M | – |
| Q1 FY2020 | Mar 31, 2020 | -$35.30M | – |
| Q4 FY2019 | Dec 31, 2019 | -$34.22M | – |
| Q3 FY2019 | Sep 30, 2019 | -$37.11M | – |
| Q2 FY2019 | Jun 30, 2019 | -$44.15M | – |
| Q1 FY2019 | Mar 31, 2019 | -$30.52M | – |
| Q4 FY2018 | Dec 31, 2018 | -$27.15M | – |
| Q3 FY2018 | Sep 30, 2018 | -$19.24M | – |
| Q2 FY2018 | Jun 30, 2018 | -$15.02M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.00M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.98M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.29M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.75M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.39M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.38M | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.40M | – |
See a number that looks wrong?